Abstract

In this work, a strategy that reconstitutes c-TACE into TACIE by a zinc nanomedicine has been proposed, which is both conceptually refined and anchored in a clinical study. A promising strategy to address the next generation of TACE is laid forward in this work by functionally reprogramming cisplatin, connecting immune activation with embolic sustained release, and bringing together nanomedicine design and interventional practice. This study advances locoregional therapy in HCC beyond tumor debulking and toward durable, immune-mediated disease control by providing a concrete and translatable realization of TACIE. It may also help in the future design of interventional treatments for a greater variety of solid tumors.

文章链接：https://doi.org/10.1016/j.scib.2026.03.042